1[1]Fisher B,Brown AM,Dimitrov NV,et al.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide,methotrxate,and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors:Results from the National Surgical Adjuvant Breast and Bowel Project B-15.J Clin Oncol,1990,8:1483
2[2]Early Breast Cancer Trialists' Collaborative Group.Polychemotherapy for early breast cancer:An overview of the randomized trials.Lancet,1998,352:930
3[3]Hutchins L,Green S,Ravdin P,et al.CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients:First results of intergroup trial in 0102.Proc Am Soc Clin Oncol,1998,17:Abst 2
4[4]Henderson IC,Berry D,Demetri GD,et al.Improved outcomes from adding sequential paclitaxel but not from eslating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.J Clin Oncol,2003,21(6):976
5[5]Martin M,Pienkowski T,Mackey J,et al.TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients,BCIRG 001:55 months follow-up.Breast Cancer Res Treat,2003,82(Suppl 1):Abstr 43
6[6]Fisher B,Dignam J,Bryant J,et al.Five versus more than five years of tamoxifen for lymph node-negative breast cancer:Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.J Natl Cancer Inst,2001,93:684
7[7]Albain KS,Green SJ,Racsin PM,et al.Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent:Initial results from intergroup trial 0100(SWOG-8814).Proc AmSoc Clin Oncol,2002,21:37
8[8]Dowsett M.Analysis of time to recurrence in the ATAC(arimidex,tamoxifen,alone or in combination)trial according to estrogen receptor and progesterone receptor status.Breast Cancer Res Treat,2003,82(Suppl 1):Abstr 4
9[9]Goss PE,Ingle JN,Martino S,et al.Randomized placebo-controlled trial of letrozole in postmenopausal women with early breast cancer completing five years of tamoxifen.Breast Cancer Res Treat,2003,82(Suppl 1 ):Abstr 42
10[10]Citro ML,Berry DA,Cirrincione C,et al.Randomized trial of dose-dense versus conventionally schedule and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of nodepositive primary breast cancer:First report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741.J Clin Oncol,2003,21(7):1431
4Walter C, Scheidhauer K, Scharl A, et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions[J]. Eur Radial, 2003, 13(7): 1651-1656.
5Scheidhauer K, Walter C, Seemann MD, et al. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions[J]. Eur J Nucl Med Mol Imaging, 2004, 31( Suppl 1): S70- S79.
6Buck AK, Schirrmeister H, Mattfeidt T, et al. Biological characterisation of breast cancer by means of PET[J]. Eur J Nucl Med Mol Imaging, 2004, 31 (Suppl 1): S80-S87.
7Kracht LW, Friese M, Herholz K, et al. Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to micovessel density in patients with.glioma[J]. Eur J Nucl Med Mol Imaging, 2003, 30(6): 868-873.
8Khan N, Oriuchi N, Ninomiya H, et al. Positron emission tomographic imaging with lIC-choline in differential diagnosis of head and neck tumors: comparison with ISF-FDG PET[J]. Ann Nucl Med, 2004, 18(5): 409-417.
9Inoue T, Kim EE, Wong FC, et al. Comparison of fluorine-18- fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors[J]. J Nucl Med, 1996, 37(9): 1472-1476.
10Leskinen-Kallio S, Nagren K, Lehikoinen P, et al. Uptake of 11Cmethionine in breast cancer studied by PET. An association with the size of S-phase fraction[J]. Br J Cancer, 1991, 64(6): 1121- 1124.
